Patent intelligence · US
US 9920311
PEGylated L-asparaginase
PEGylated L-asparaginase
Patent details — US 9920311
- Jurisdiction
- US
- Status
- granted
- Grant date
- Mar 20, 2018
- Expiration
- Mar 15, 2038
- Applicant
- Jazz Pharmaceuticals II SAS
- Claims
- 14
- CPC classes
- A61K, A61K38/50, A61K47/60, A61P
Quick answer
US 9920311 (PEGylated L-asparaginase) is held by Jazz Pharmaceuticals II SAS. Status: granted. Granted Mar 20, 2018. Expires Mar 15, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Jazz Pharmaceuticals II SAS
- Grant date
- Expiration
- Claims
- 14
- CPC classes
- A61K, A61K38/50, A61K47/60, A61P, A61P35/00, A61P35/02
More from Jazz Pharmaceuticals II SAS
Related pharmaceutical patents in our USPTO index.
-
US 12427160
Use of cannabinoids in the treatment of epilepsy
granted -
US 12403136
Cannabinoid derivatives as pharmaceutically active compounds and methods of preparation thereof
granted -
US 12396963
Cannabidiol-type cannabinoid compound
granted -
US 12383512
Cannabidiol-type cannabinoid compound
granted -
US 12383567
Use of cannabinoids in the treatment of epilepsy
granted -
US 12364670
Cannabidiol-type cannabinoid compound
granted -
US 12357586
Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy
granted -
US 12350253
Use of cannabinoids in the treatment of dyskinesia associated with parkinson's disease
granted
Frequently asked questions
What is US patent 9920311?
US 9920311 (PEGylated L-asparaginase) is held by Jazz Pharmaceuticals II SAS. Status: granted. Granted Mar 20, 2018. Expires Mar 15, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9920311?
Jazz Pharmaceuticals II SAS is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 89 pharmaceutical patents for this assignee.
When does US 9920311 expire?
Our index shows an expiration date of Mar 15, 2038 (12 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.